VYNE Therapeutics (NASDAQ:VYNE) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note published on Monday,Benzinga reports. The firm currently has a $5.75 price objective on the stock.

Separately, BTIG Research assumed coverage on shares of VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 price objective for the company.

VYNE Therapeutics Trading Up 15.6 %

Shares of VYNE opened at $4.00 on Monday. The stock has a market cap of $59.00 million, a P/E ratio of -4.65 and a beta of 1.30. VYNE Therapeutics has a 1 year low of $1.57 and a 1 year high of $4.00. The stock’s 50-day moving average price is $2.89 and its two-hundred day moving average price is $2.28.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for approximately 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th largest position. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics as of its most recent filing with the SEC. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.